Open Access Highly Accessed Email this article to a friend

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

Andreas G Niethammer†, Heinz Lubenau†, Gerd Mikus, Philipp Knebel, Nicolas Hohmann, Christine Leowardi, Philipp Beckhove, Mustafa Akhisaroglu, Yingzi Ge, Marco Springer, Lars Grenacher, Markus W Buchler, Moritz Koch, Jürgen Weitz, Walter E Haefeli and Friedrich H Schmitz-Winnenthal*

BMC Cancer 2012, 12:361 doi:10.1186/1471-2407-12-361

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive BMC Cancer's emails?